EpiPen's seller Mylan drew criticism last summer for having hiked its price by more than 500 percent over the past decade. » Read More
By: David Oliver, associate editor, social media
Doing this one thing can lead to improvements in cognitive abilities, regardless of your current brain health, David Oliver writes in US News & World Report. » Read More
By: Dan Mangan
Ending $10 billion in payments for cost-sharing assistance would lead to the U.S. to pay out more $12 billion in other subsidies. » Read More
Medicare ratings cuts at Humana may signal a higher bar for other Medicare insurers, an analyst says.
Humana fell Wednesday after a report by the Centers for Medicare and Medicaid Services showed its membership highly rated Medicare plans declined.
Federal health officials and the drug company Mylan are refusing to explain why full rebates for EpiPen are being delayed.
Illumina shares sink after the company trimmed its third-quarter revenue projections.
Zocdoc wants to make "Unsick Days" common, so workers can get checkups during a paid day off without having to worry about repercussions.
Shares of Bristol-Myers Squibb fell 10 percent, after the Opdivo trial result did not meet expectations.
Mylan soared Monday after it agreed to pay $465 million to settle charges that it overcharged the government for its EpiPen products.
After being largely ignored during the first presidential debate, the Affordable Care Act just got a lot of attention from Clinton and Trump.
Bristol-Myers Squibb's approach to treating lung cancer will have a chance to redeem itself when new data comes out on Sunday.
It's not clear when EpiPen owner Mylan was told by health officials it was misclassifying the anti-allergy device for rebate purposes.
Many hospitals in the path of the hurricane altered their operations.
Alnylam Pharmaceuticals said it would halt development of an experimental therapy for a rare genetic condition that can cause heart failure.
UBS initiates coverage on CVS Health with a buy rating.
Former Silicon Valley darling Theranos will close its labs and Wellness Centers, CEO Elizabeth Holmes revealed in a public letter to "stakeholders."
The federal government said Medicaid has spent nearly $800 million on EpiPens since 2011.
People who sign up in Obamacare coverage outside open enrollment tend to spend less time enrolled in plans.
The world's oldest people may have attained the oldest age biologically possible for the human species.
Mylan should be paying higher Medicaid rebates for its EpiPen devices, health officials say.
A switch in health insurers is making a big difference for some employees at Activision Blizzard.
More than 2 million people would get subsidies to reduce their premiums, but aren't because they buy outside of Obamacare exchanges.
Get the best of CNBC in your inbox